The Ozempic boom is slowing down

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish pharmaceutical giant warns that sales growth for all its drugs — including Ozempic — is expected to slow in the coming year.Read more…

About Author

Bruce Gil

See author's posts

The Ozempic boom is slowing down

About Author

Bruce Gil

May & Baker targets N41bn revenue in 2025

Marquis Who’s Who Honors Neely Frye for Expertise in Health Care in the Government Sector

Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation

Novo’s Weight Loss Drugs Removed from FDA Shortage List

‘Active recovery’ after exercise is supposed to improve performance—but does it really work?

The Surprising Source of Next-Gen Antibiotics: Oyster Blood

New GLP-1 Data Reinforce CV Benefit

Tool Predicts Whether One Bruise in Pediatric ED Signals Abuse

Unclogging the immune system: Scientists use immunotherapy to remove aging cell buildup

The 11 Best Winter Jackets for Men, Tested by Style Editors

Propranolol reduces tremors in Parkinson’s disease

The 6 Best Adjustable Kettlebells, Tested by Editors and Certified Trainers

Philips Norelco Multigroom Series 9000 Review: A Trimmer That Does It All

Novo’s Weight Loss Drugs Removed from FDA Shortage List

‘Active recovery’ after exercise is supposed to improve performance—but does it really work?

The Surprising Source of Next-Gen Antibiotics: Oyster Blood

New GLP-1 Data Reinforce CV Benefit

Tool Predicts Whether One Bruise in Pediatric ED Signals Abuse

About PhaMed

Recent News

About Author

More Stories

You may have missed

About PhaMed

Recent News

Categories